CLR 131 Granted Orphan Drug Status in Europe for Myeloma Treatment
CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug status by the European Commission…
José Lopes, PhD, managing science editor — 
Articles by José Lopes
Triple Therapies Best, But Revlimid with Dexamethasone Could Work in Some Difficult-to-Treat Myelomas, Study Shows
Although triple therapies with Revlimid (lenalidomide) should be prioritized in patients with relapsed or refractory multiple myeloma (RRMM), combining this therapy with…
Adding Darzalex to a Velcade-Revlimid Combo Boosts Cancer Disappearance in Newly Diagnosed Multiple Myeloma, Phase 2 Trial Shows
Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing…
Empliciti Combo Prolongs Survival in Difficult-to-Treat Multiple Myeloma, New Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease progression in patients with relapsed…
AMG 420 Immunotherapy Effective in Difficult-to-treat Multiple Myeloma, Early Study Results Show
The investigational immunotherapy AMG 420 lessened tumor burden and led to cancer disappearing in half of the patients with relapsed or refractory multiple…
Similar Efficacy and Safety Seen Between Under-the-Skin Formulation and Intravenous Darzalex for Myeloma, Phase 3 Trial Shows
An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing tumor burden and has comparable…
Revlimid Becomes Option for First-line Multiple Myeloma Treatment in England
The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide) and dexamethasone for multiple myeloma…
GSK Compound Showing Durable Response Rates in Advanced Multiple Myeloma, New Phase 1 Trial Data Find
New data from a Phase 1 clinical trial show treatment with GlaxoSmithKline‘s investigational antibody-drug conjugate, GSK2857916, was linked to year free of disease progression in…
OncoTracker Acquires Global Rights to Diagnostic Test, Possible Combo Therapy for Multiple Myeloma
OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in an agreement with the…
FDA Delays Decision on Selinexor’s Approval for Heavily Treated Multiple Myeloma
The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of selinexor in combination with dexamethasone…